Should immunotherapy be added to standard of care neoadjuvant chemotherapy in borderline resectable MSI-H adenocarcinoma of pancreas?

This is definitely an area worth of trials. We know of the degree of efficacy and tolerability of chemotherapies in this setting. We also are aware of the potential for deep and prolonged response to PD-1 inhibition in patients with MSI-H + high TMB + MMR-d by IHC. I try to utilize immunotherapy in ...

This should only be done in the setting of a clinical trial! There is some data in this space, but we do not comprehensively know the implications of this on getting to surgery. The goal of neoadjuvant is downstaging, testing biology, and improving surgical outcomes. That being said, in such patient...